320 related articles for article (PubMed ID: 9425933)
61. [Measurement of bile acid N-acetylglucosaminides in serum and urine of patients with chronic liver diseases during ursodeoxycholic acid treatment].
Kimura A; Nakamura K; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1995 Mar; 92(3):224-32. PubMed ID: 7731091
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of total serum bile acids concentration and bile acid profiles in healthy cats after oral administration of ursodeoxycholic acid.
Day DG; Meyer DJ; Johnson SE; Weisbrode SE; Thudium DT; Rhodes DC
Am J Vet Res; 1994 Oct; 55(10):1474-8. PubMed ID: 7998707
[TBL] [Abstract][Full Text] [Related]
63. Variable clinical spectrum of the most common inborn error of bile acid metabolism--3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency.
Subramaniam P; Clayton PT; Portmann BC; Mieli-Vergani G; Hadzić N
J Pediatr Gastroenterol Nutr; 2010 Jan; 50(1):61-6. PubMed ID: 19915491
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of ursodeoxycholic acid bioavailability from immediate- and sustained-release preparations using gas chromatography-mass spectrometry and high-performance liquid chromatography.
Scalia S; Scagliarini R; Pazzi P
Arzneimittelforschung; 2000 Feb; 50(2):129-34. PubMed ID: 10719615
[TBL] [Abstract][Full Text] [Related]
65. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
66. The profile of bile acids and their sulfate metabolites in human urine and serum.
Bathena SP; Mukherjee S; Olivera M; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 942-943():53-62. PubMed ID: 24212143
[TBL] [Abstract][Full Text] [Related]
67. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis.
Invernizzi P; Setchell KD; Crosignani A; Battezzati PM; Larghi A; O'Connell NC; Podda M
Hepatology; 1999 Feb; 29(2):320-7. PubMed ID: 9918905
[TBL] [Abstract][Full Text] [Related]
68. Urinary bile acids in women treated with contraceptive steroids. A study using computerized gas chromatography-mass spectrometry.
Thomassen PA
Acta Obstet Gynecol Scand; 1981; 60(2):173-6. PubMed ID: 7246083
[TBL] [Abstract][Full Text] [Related]
69. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid.
Glantz A; Marschall HU; Lammert F; Mattsson LA
Hepatology; 2005 Dec; 42(6):1399-405. PubMed ID: 16317669
[TBL] [Abstract][Full Text] [Related]
70. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
[TBL] [Abstract][Full Text] [Related]
71. Human liver class I alcohol dehydrogenase gammagamma isozyme: the sole cytosolic 3beta-hydroxysteroid dehydrogenase of iso bile acids.
Marschall HU; Oppermann UC; Svensson S; Nordling E; Persson B; Höög JO; Jörnvall H
Hepatology; 2000 Apr; 31(4):990-6. PubMed ID: 10733557
[TBL] [Abstract][Full Text] [Related]
72. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
73. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice.
Pelletier G; Roulot D; Davion T; Masliah C; Causse X; Oberti F; Raabe JJ; Van Lemmens C; Labadie H; Serfaty L;
Hepatology; 2003 Apr; 37(4):887-92. PubMed ID: 12668982
[TBL] [Abstract][Full Text] [Related]
74. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
75. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
76. Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.
Güldütuna S; Leuschner M; Wunderlich N; Nickel A; Bhatti S; Hübner K; Leuschner U
Eur J Clin Pharmacol; 1993; 45(3):221-5. PubMed ID: 8276045
[TBL] [Abstract][Full Text] [Related]
77. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
Kappler M; Espach C; Schweiger-Kabesch A; Lang T; Hartl D; Hector A; Glasmacher C; Griese M
Aliment Pharmacol Ther; 2012 Aug; 36(3):266-73. PubMed ID: 22670841
[TBL] [Abstract][Full Text] [Related]
78. LC/ESI-tandem mass spectrometric determination of bile acid 3-sulfates in human urine 3beta-Sulfooxy-12alpha-hydroxy-5beta-cholanoic acid is an abundant nonamidated sulfate.
Goto T; Myint KT; Sato K; Wada O; Kakiyama G; Iida T; Hishinuma T; Mano N; Goto J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 846(1-2):69-77. PubMed ID: 16949895
[TBL] [Abstract][Full Text] [Related]
79. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
80. Urinary bile acids: a noninvasive measure of liver function and bile acid metabolism?
Suchy FJ
J Pediatr Gastroenterol Nutr; 1984 Nov; 3(5):649-51. PubMed ID: 6502366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
